

Gene Therapy Restores the Transcriptional Program of Hematopoietic Stem Cells in Fanconi Anemia

RUNNING TITLE

scRNA seq following Gene Therapy in FA HSPCs

AUTHORS

Miren Lasaga^{1*}, Paula Río^{2,3,4*}, Amaia Vilas-Zornoza^{5,6,*}, Nuria Planell¹, Susana Navarro^{2,3,4}, Diego Alignani⁷, Beatriz Fernández-Varas^{3,8}, Josune Zubizaray⁹, Roser M. Pujol^{3,10,11}, Eileen Nicoletti¹², Jonathan D. Schwartz¹², Julián Sevilla^{3,9}, Marina Ainciburi^{5,6}, Asier Ullate-Agote^{5,6}, Jordi Surrallés^{3,10,11}, Rosario Perona^{3,8,13}, Leandro Sastre^{3,8}, Felipe Prosper^{5,6,&}, David Gomez-Cabrero^{1,14,15,&} and Juan A. Bueren^{2,3,4,&}.

AFFILIATIONS

¹Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain.

²Hematopoietic Innovative Therapies Division, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain.

³Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.

⁴Instituto de Investigaciones Sanitarias. Fundación Jiménez Díaz, Madrid, Spain.

⁵Area de Hemato-Oncología, Centro de Investigación Médica Aplicada (CIMA), and Servicio de Hematología y Terapia Celular, Clínica Universidad de Navarra, IDISNA, Pamplona, Spain.

⁶Centro de Investigación Biomédica en Red de Cáncer, CIBERONC.

⁷Flow Cytometry Core, CIMA, Universidad de Navarra, Pamplona, Spain.

⁸Instituto de Investigaciones Biomédicas Alberto Sols, CSIC/UAM.

⁹Hemoterapia y Hematología Pediátrica, Fundación para la Investigación Biomédica, Hospital Infantil Universitario Niño Jesús, Madrid, Spain.

¹⁰Departamento de Genética y Microbiología, Universitat Autònoma de Barcelona, Barcelona, Spain;

29 ¹¹Fundación Instituto de Investigación del Hospital de la Santa Creu y Sant Pau, Barcelona,
30 Spain;

31 ¹²Rocket Pharmaceuticals Inc, New York, NY, USA

32 ¹³ Instituto de Salud Carlos III, Madrid, Spain

33 ¹⁴Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah
34 University of Science and Technology KAUST, Thuwal, Saudi Arabia.

35 ¹⁵Mucosal & Salivary Biology Division King's College London Dental Institute, London, United
36 Kingdom.

37

38 *Equal first author contribution.

39 &Corresponding authors with equal contribution. Juan A. Bueren. Email: juan.bueren@ciemat.es;
40 David Gomez-Cabrero. Email: david.gomezcabrero@kaust.edu.sa; Felipe Prosper
41 Email:fprosper@unav.es.

42

43 **ABSTRACT**

44 Fanconi anemia (FA) is an inherited disease associated with marked hematopoietic stem and
45 progenitor cell (HSPC) defects. Ongoing clinical trials have shown that lentiviral-mediated gene
46 therapy can ameliorate bone marrow failure (BMF) in non-conditioned FA patients thanks to the
47 proliferative advantage of corrected FA HSPCs. Here we investigated whether gene therapy can
48 revert affected molecular pathways in diseased HSPCs, a question not previously addressed in
49 any HSC gene therapy trial. Single-cell RNA sequencing was performed in chimeric populations
50 of corrected and uncorrected HSPCs coexisting in BM of gene therapy treated FA patients. Our
51 study demonstrates that gene therapy reverts the transcriptional signature of FA HSPCs, which
52 then resembles the transcriptional program of healthy donor HSPCs. This includes a
53 downregulated expression of TGF- β and p21, typically upregulated in FA HSPCs, and
54 upregulation of DNA damage response and telomerase maintenance pathways. Our results show
55 for the first time the potential of gene therapy to rescue defects in the HSPC transcriptional
56 program from patients with inherited diseases, in this case in FA characterized by BMF and
57 cancer predisposition.

58

59 INTRODUCTION

60
61 The potential of gene therapy (GT) to correct a variety of human inherited diseases, including
62 primary immunodeficiencies and hemoglobinopathies has been well demonstrated in previous
63 clinical studies (Ferrari, Thrasher et al., 2021). Additionally, we have recently shown that
64 lentiviral-mediated GT can also enable correction of more complex diseases, such as Fanconi
65 anemia (FA), in which marked phenotypic defects are already evident in the self-renewing
66 HSCs. As previously reported, the infusion of corrected CD34⁺ cells in non-conditioned FA
67 patients resulted in a marked HSPC proliferative advantage, which facilitates the progressive
68 increase in the number of bone marrow (BM) and peripheral blood (PB) gene-corrected cells
69 (Rio et al., 2019).

70 Despite significant advances in the field of GT, the full potential of this therapeutic modality will
71 depend on its capacity to reestablish the molecular circuits and the functional potential of
72 diseased cells. This is even more relevant in syndromes such as FA, characterized by DNA repair
73 defects resulting in progressive accumulation of DNA damage, and additional molecular
74 responses triggered by a defective FA/BRCA pathway. In patients treated in the FANCOLEN-I
75 clinical trial, the presence of a chimeric population of corrected and uncorrected FA HSPCs,
76 none of them exposed to any conditioning agent, let us comparatively investigate the differential
77 molecular pathways that characterize each of these populations coexisting in the BM of these
78 patients (**Fig.1**). This approach allowed us to demonstrate that lentiviral-mediated GT not only
79 mediates a progressive engraftment of FA patients with gene corrected HSPCs, but also results in
80 the reprogramming of the transcriptional signature of FA HSPCs, which then resembles the
81 molecular circuits of healthy HSPCs, thus accounting for the phenotypic correction of FA
82 HSPCs.

83 RESULTS

84 Gene therapy modifies the HSPC transcriptional program in FA patients

85 Bone marrow (BM) CD34⁺ cells from four FA-A patients (FA-02002, FA-02004, FA-02006, and
86 FA-02008) who had respectively been treated with gene therapy 5, 4, 3, and 2 years previously,
87 were purified and analyzed by single-cell RNA sequencing (scRNAseq), as described in **Fig 1**.

88 qPCR analyses from these samples showed the presence of 0.77 vector copy numbers (VCN) per
89 cell in the BM of patient 02002, and 0.45, 0.26, and 0.29 VCNs per cell in purified CD34⁺ cells
90 in patients FA-02004, FA-02006, and FA-02008 respectively (see Materials and methods). Since
91 the average VCN per corrected cell was of 1.0 copies(Rio, Navarro et al., 2019), the proportion
92 of corrected cells in these patients is estimated to be 77%, 45%, 26%, and 29%, respectively,
93 revealing the chimeric nature of the HSPC populations residing in their BM.

94 CD34⁺ cells from FA patients were classified according to transcriptional profiles previously
95 described(Velten, Haas et al., 2017, Zheng, Terry et al., 2017), which identified twelve different
96 HSPC clusters that corresponded to primitive HSCs and more committed lympho-hematopoietic
97 progenitor cells (See analyses from patient FA-02006 in **Fig. 2A**; and patients FA-02002, FA-
98 02004 and FA-02008 in **Fig. S1A, B, C, D**). To investigate the impact that GT had in the
99 transcriptional program of FA HSPCs, CD34⁺ cell subpopulations from GT-treated FA patients
100 were classified as FANCA⁺ and FANCA⁻, based on the expression of *FANCA* by scRNAseq (see
101 materials and methods). As shown in **Fig. 2B** and **2C**, the presence of FANCA⁺ cells was
102 evident in all HSPC populations represented with at least 30 cells per cluster. No significant
103 differences in the proportion of FANCA⁺ cells present in these subpopulations were observed
104 among the four patients (**Table S1**). Additionally, a wide range of FANCA expression was
105 observed in samples analyzed, although higher expression levels were observed in most HSPC
106 subpopulations from patient FA02002, compared with the other patients (**Fig. 2D**).

107 To investigate the impact that ectopic FANCA expression had in the transcriptional program of
108 HSPCs, we performed a differential expression analysis between FANCA⁺ and FANCA⁻ HSPCs
109 present in each GT-treated patient. As shown in **Fig. 2E**, the ectopic expression of *FANCA*
110 upregulated a high number of genes compared to the number of genes that were downregulated.
111 As expected, genes with statistically differential expression corresponded to subpopulations with
112 a higher representation (i.e., monocytic CD34⁺ cells; genes with significantly up-regulated and
113 down-regulated expression (p-value< 0.001) are shown in dark red and dark blue bars,
114 respectively in **Fig. 2E**). Remarkably, most of the upregulated and downregulated genes in
115 FANCA⁺ vs. FANCA⁻ cells showed the same expression pattern in each of the analyzed patients
116 (see fifth bar at the bottom of each patient's bars in **Fig. 2E**). To select the genes with a robust
117 differential expression between FANCA⁺ versus FANCA⁻ HSPCs, we considered those genes

118 that showed a significant differential expression ($\text{abs}(\log\text{FC}) > 0.25$ and adjusted $p\text{-value} < 0.05$) in
119 at least one cell type and in at least three patients. In addition, changes in gene expression should
120 be in the same direction in all the four patients. Based on these criteria, a total number of 152
121 differentially expressed genes were identified (See **Table S2**).

122 Taken together, data obtained in these analyses indicate that the ectopic expression of *FANCA*
123 induced long-term reproducible changes in the gene expression program of HSPCs from FA-A
124 patients.

125 **Gene therapy reprograms the transcriptional signature of FA HSPCs towards the** 126 **transcriptional profile characteristic of healthy HSPCs**

127 Next, we investigated whether changes in the transcriptional program of gene-corrected FA-A
128 HSPCs resembled profiles characteristic of healthy HSPCs. To this end, scRNAseq data from
129 GT-treated FA CD34⁺ cells was compared with that obtained from HD CD34⁺ cells. As shown in
130 **Fig. 3A** (see also **Expanded View Figure S2**) the ectopic expression of *FANCA* (FANCA⁺ cells)
131 was detected in the different CD34⁺ cell clusters. Additionally, **Fig. 3B** shows that *FANCA*
132 expression levels in the different HSPC subpopulations are highly heterogeneous, not only in the
133 case of GT-treated FA patients, but also in HDs. Despite this heterogeneity, in eight out of the
134 twelve HSPC subpopulations, physiological levels of *FANCA* mRNA were significantly higher
135 in HD HSPCs compared with the corresponding values observed in FANCA⁺ HSPCs from GT-
136 treated FA patients. This observation is consistent with the average insertion of 1 proviral
137 *FANCA* copy per corrected cell after GT, in comparison with the 2 copies of WT *FANCA* per HD
138 cell, and also with the moderate activity of the phosphoglycerate kinase (PGK) promoter that
139 was selected for the therapeutic vector because of its favorable safety profile.

140 To investigate if GT reprogrammed the transcriptional signature of FA HSPCs towards the one
141 corresponding to HD HSPCs, additional gene expression analyses were conducted in HD and FA
142 HSPCs, focusing on the 152 genes that showed significant expression changes between FANCA⁺
143 and FANCA⁻ HSPCs in GT treated patients (See **Figure 2E** and **Table S2**). In these studies,
144 three different comparisons were performed in each of the twelve HSPC subpopulations:
145 FANCA⁺ vs. FANCA⁻ HSPCs from GT-treated FA patients (GT-FA HSPCs); HD HSPCs vs.
146 FANCA⁻ GT-FA HSPCs; and finally, HD HSPCs vs. FANCA⁺ GT-FA HSPCs (**Fig. 3C**). As

147 observed in analyses of **Fig. 2**, significant differences (dark red or blue spots in **Fig. 3C**) were
148 most evident in HSPC subpopulations with a higher representation (i.e. monocyte CD34⁺ cells;
149 p-value<0.001).

150 Regarding the comparison of GT-FANCA⁺ vs. GT-FANCA⁻ HSPCs (**Fig. 3C** first column),
151 several differentially expressed genes with relevance in FA have been marked (see right side of
152 the figure). Interestingly, genes involved in functions such as DNA repair or cell cycle were
153 upregulated in GT-FANCA⁺ vs GT-FANCA⁻ cells. In the second column of **Fig. 3C**, the gene
154 expression pattern of HSPCs from HDs was compared with that corresponding to uncorrected
155 HSPCs from GT-treated patients (HD vs GT-FANCA⁻). Strikingly, most of the transcriptional
156 changes observed between these populations resembled changes seen between corrected and
157 uncorrected FA HSPCs (first column in **Fig. 3C**) (see **Table S3** for detailed analyses per cell
158 type using two complementary statistical analyses). Finally, in contrast to the above-mentioned
159 observations, the comparison of the transcriptional program of HD HSPCs vs FANCA⁺ HSPCs
160 from GT-treated FA patients (third column in **Fig 3C**) showed limited changes, most of which
161 were not significant and not related to differences noted when HD or corrected FA HSPCs were
162 compared with uncorrected FA HSPCs. Overall, these studies demonstrate that lentiviral-
163 mediated GT reverts the gene expression program of FA HSPCs, which then acquire an
164 expression pattern that resembles the signature characteristic of healthy HSPCs.

165 **Lentiviral-mediated gene therapy reverts molecular pathways characteristic of FA HSPCs**

166 Having observed that the ectopic expression of *FANCA* in FA HSPCs reverts the transcriptional
167 signature of these cells to resemble a healthy HSPC signature, we next performed a gene-set
168 enrichment analysis to determine changes in relevant pathways associated with FA. These
169 include pathways related to DNA damage response and repair, cell cycle checkpoint, cell aging,
170 and telomerase maintenance (see materials and methods). As shown in **Fig. 4** and **Table S4**, an
171 upregulated expression of several of these pathways was observed when FANCA⁺ and FANCA⁻
172 HSPCs present in each of the GT-treated patients were compared (See first paired columns in
173 **Fig. 4**; GT-FANCA⁺ vs GT-FANCA⁻). Moreover, an almost identical upregulation of these
174 pathways was observed when HSPCs from HDs were compared with FANCA⁻ HSPCs from GT-
175 treated patients (HD vs GT-FANCA⁻; second paired columns in **Fig. 4**).

176

177 A deeper comparative expression analysis of genes involved in the cell cycle control was then
178 performed between FANCA⁺ and FANCA⁻ HSPCs from GT-treated patients (GT-FANCA⁺ vs
179 GT-FANCA⁻; see external crowns in **Fig. 5A**). Similar comparisons were also made between HD
180 HSPCs and FANCA⁻ HSPCs from GT-treated patients (internal crowns in **Fig. 5A**). As shown,
181 the ectopic expression of FANCA was associated with the downregulation of *TGF-β* in every
182 patient, and also of *p21* (*CDKN1A*) in two of the four GT-treated FA patients. On the other hand,
183 a number of cyclins and mini-chromosome maintenance (MCM) genes were upregulated in
184 corrected vs uncorrected FA HSPCs (FANCA⁺ vs FANCA⁻ HSPCs). Notably, when similar
185 comparisons were performed between HD HSPCs and FANCA⁻ HSPCs from GT-treated FA
186 patients, almost identical gene expression changes were observed (**Fig. 5A**), indicating that the
187 behavior of cell cycle and DNA checkpoint pathways in corrected FA-A HSPCs resembled the
188 pathways characteristic of healthy HSPCs.

189 Since previous studies have shown that p21 participates in the transcriptional repression of
190 different genes of the FA/BRCA pathway (Jaber, Toufektchan et al., 2016, Rego, Harney et al.,
191 2012) changes in the expression of FA/BRCA genes were also comparatively investigated in
192 FANCA⁺ and FANCA⁻ HSPCs from GT-treated patients. As shown in **Fig. 5B**, in addition to
193 *FANCA*, several other genes participating in the FA/BRCA pathway, including *FANCB*, *FANCI*,
194 *FANCD2*, *FANCG*, *UB2T* (*FANCT*), *BRCA2*, *PALB2*, *BRCA1* and *BRIP1* (*FANCI*) were
195 upregulated in GT-FANCA⁺ vs. GT-FANCA⁻ HSPCs. Again, many of these genes were also
196 upregulated when HD HSPCs were compared with uncorrected GT-FANCA⁻ HSPCs.

197 This set of studies thus demonstrate that GT reverts physiologically relevant molecular pathways
198 that are severely affected in HSPCs from FA patients

199 **Functional implications of the restored transcriptional program of corrected FA- HSPCs**

200 In a final set of experiments, we investigated the functional implications associated with the
201 restored transcriptional program of gene corrected FA HSPCs. First, we investigated if the
202 restored DNA repair pathways had a direct implication in the correction of the hypersensitivity
203 of FA-HSPCs to inter-strand crosslinking agents such as mitomycin C (MMC). While colony
204 forming cells (CFCs) from the four patients were highly sensitive to MMC prior to the infusion
205 of corrected HSPCs (no colonies were generated when cells were exposed to 10 nM MMC),

206 survival of these cells to MMC was markedly increased 2 to 5 years after GT (22.3% to 67.3% of
207 CFCs survived in 10 nM MMC; **Figure 6A**). Consistent with these studies, the percentage of T
208 cells with diepoxybutane (DEB)-induced aberrant chromosomes was also markedly decreased
209 after GT of FA-A patients (Figure 6B). Overall, these studies confirm the functional implications
210 associated with the restoration of the DNA repair pathways observed in the scRNAseq analyses
211 shown in **Fig. 4**.

212 Finally, since scRNAseq studies also showed the restoration of telomere maintenance pathways,
213 we studied changes in the telomere length of PB cells from the four FA patients included in this
214 study. In particular, we evaluated changes that took place from the 15th day post-infusion, when
215 the proportion of corrected cells was still undetectable, to the 2nd -5th year post-infusion. As a
216 negative control, changes in the telomere length of PB cells from three FA-A patients with no
217 significant engraftment of corrected cells (VCN<0.008; control FA group) were investigated at
218 comparable time points. While a clear reduction in the telomere length was observed in PB cells
219 from the negative control group, a stabilization or even elongation was observed in GT treated
220 patients 2-5 years after infusion of corrected cells. Also of interest is the comparison of the
221 telomere length of PB cells from HDs of the same age, which indicated that telomeres from GT-
222 treated patients were still below values corresponding to HDs.

223 Overall, the results obtained in this study demonstrate for the first time that GT - in particular the
224 lentiviral-mediated GT in FA patients - reverts the transcriptional program of diseased HSPCs,
225 which then display gene expression signatures, molecular pathways and cellular phenotypes
226 which then resemble the physiological status of healthy HSPCs.

227 **DISCUSSION**

228 Gene therapy has emerged as a safe and efficient therapeutic option for diverse monogenic
229 disorders affecting the hematopoietic system (See review in (Ferrari et al., 2021)). In a previous
230 study we showed for the first time preliminary clinical evidence of safety and efficacy of GT in a
231 more complex genetic disease, such as FA (Rio et al., 2019). In that clinical study we
232 demonstrated that the ectopic expression of FANCA reproducibly conferred engraftment and
233 proliferative advantage of corrected HSCs in non-conditioned FA-A patients. Nonetheless, the
234 question of whether corrected FA HSPCs acquire the transcriptional profile characteristic of

235 healthy HSPCs was not addressed in our previous study, nor in any other GT trial of a
236 monogenic disease.

237 By leveraging scRNAseq profiling we have extended the conclusions from our previous study
238 towards the evaluation of changes in the transcriptional program of corrected versus uncorrected
239 HSPCs that coexist in the BM of the same patient. These analyses and also gene expression
240 comparisons performed with respect to HD HSPCs allowed us to demonstrate for the first time
241 that GT not only corrects the expression of the mutated gene (*FANCA* in this case), but also
242 reprograms the molecular circuits of diseased FA-A HSPCs, which then acquire a normalized
243 gene expression pattern characteristic of healthy HSPCs.

244 Importantly, the restored expression of *FANCA* decreased the expression of two genes with
245 particular implications in FA, *TGF- β* and *p21*. Increased mRNA levels of these two genes have
246 been observed in HSPCs from FA patients and murine FA models and are believed to contribute
247 to the BMF characteristic of the disease (Ceccaldi, Parmar et al., 2012, Zhang, Kozono et al.,
248 2016). Notably, previous studies have shown that p21 downregulates *USP1* upon exposure to
249 DNA damage, disrupting FANCD2/L mono-ubiquitination and nuclear foci formation (Rego et
250 al., 2012). Additional studies have also shown that several genes involved in the telomere
251 biology and in the FA/BRCA pathway are downregulated via the p21/E2F4 pathway (Jaber et al.,
252 2016). Although it might be expected that p53 and Myc – which have been shown to be
253 upregulated in FA patients (Ceccaldi et al., 2012, Rodríguez, Zhang et al., 2021) – should be also
254 downregulated in corrected FA HSPCs, our data do not support this hypothesis. Reasons
255 accounting for these apparent unexpected observations could be related either with the enhanced
256 expression of cell cycle genes in corrected FA HSPCs, with post-transcriptional regulatory
257 mechanisms involved in p53 expression (Ceccaldi et al., 2012), or also with the moderate BMF
258 status of the FA patients enrolled in the FANCOLEN I trial (Rio et al., 2019).

259 Our study also shows that several defective pathways implicated in the FA cellular phenotype
260 were significantly upregulated as a result of the ectopic expression of *FANCA* in FA-A HSPCs.
261 Among all, the restoration of DNA repair related pathways has enormous implications in FA GT
262 since this accounts for the correction of the hypersensitivity of BM progenitors and PB T cells to
263 genotoxic drugs, such as MMC and DEB.

264 Also of note was the observation of the increased expression of mini-chromosome maintenance
265 (MCM) helicase genes in corrected FA-A HSPCs. Previous studies have shown that decreased
266 levels of MCM proteins are associated with the HSC hypersensitivity to replication stressors
267 (Flach, Bakker et al., 2014), and have shown a relationship between FA and accelerated ageing
268 (Brosh, Bellani et al., 2017). Strikingly, our study shows for the first time that corrected FA-A
269 HSPCs upregulates the expression of MCM, emulating the MCM expression observed in HD
270 HSPCs, and suggesting that genetic correction should reduce the replication stress and contribute
271 to the rejuvenation of the HSCs from FA patients. Importantly, our study has also shown that GT
272 upregulates several genes associated with the telomere biology, and revealed for the first time the
273 maintenance or even elongation of the telomere length in PB cells from FA patients after 2-5
274 years post-GT. This observation contrasts with the progressive telomere attrition previously
275 characterized in FA patients (Savage & Alter, 2008), and also with the negative FA control
276 group included in our study. It is currently unknown whether GT will prevent the progressive
277 telomere attrition characteristic of the disease, or even extend the telomere length of corrected
278 hematopoietic cells to levels observed in HD cells.

279 Taken together, our study demonstrates for the first time that GT reverts the transcriptional
280 program and defective molecular pathways in corrected FA HSPCs. This observation has a
281 particular impact in FA and possibly in other HSC diseases characterized by DNA repair defects,
282 since here we demonstrate that GT restores the molecular pathways of FA HSPCs towards a
283 signature characteristic of healthy HSPCs.

284 **MATERIAL AND METHODS**

285 **Patients and Healthy donors**

286 FA patients included in this study, FA-02002, FA-02004, FA-02006 and FA-02008, were FA-A
287 patients enrolled in the FANCOLEN-1 gene therapy trial (FANCOLEN-1; ClinicalTrials.gov,
288 NCT03157804; European Clinical Trials Database, 2011-006100-12) and complied with all
289 relevant ethical regulations approved by the ethics committees at Hospital Vall d’Hebron in
290 Barcelona and Hospital del Niño Jesús in Madrid.

291 Patients were infused with autologous CD34⁺ cells after transduction with the therapeutic PGK-
292 *FANCA.Wpre** LV (Gonzalez-Murillo, Lozano et al., 2010). Recent clinical data has shown that

293 although no conditioning was given to these patients prior to cell infusion, a progressive
294 engraftment of corrected cells took place over time, implying the presence of a chimeric
295 population of corrected and uncorrected cells in their hematopoietic tissues (Rio et al., 2019). For
296 the participation of healthy donors (HDs) in this study (median age = 20 y/o), BM aspiration was
297 performed after provision of informed consent, which was approved by the clinical research
298 ethics committee of Clínica Universidad de Navarra.

299 **Bone marrow cells**

300 Bone marrow cells from GT treated patients were obtained in the course of routine follow-up
301 studies of the GT trial and as part of additional exploratory studies. Samples used in these studies
302 were obtained 5 years (FA-02002), 4 years (FA-02004), 3 years (FA-02006) and 2 years (FA-
303 02008) after infusion of transduced CD34⁺ cells, respectively. Patients FA-02004 and FA-02008
304 had been treated with eltrombopag to stimulate hematopoiesis 12 and 6 months prior to the
305 evaluation of BM cells, respectively. In all instances samples were processed immediately after
306 BM aspiration.

307 For the purification of CD34⁺ cells, erythrocytes were lysed with ammonium chloride lysis
308 solution (0.155 mmol/L NH₄Cl + 0.01 mmol/L KHCO₃ + 10⁻⁴ mmol/L EDTA), washed using
309 PBS (Gibco) + 0.2% BSA (10%) + 2% PenStrep (Gibco) and stained using CD45 APC (clone
310 2D1; Biolegend) and CD34 PECY7 (clone 4H11; eBiosciences) for 30 min at 4°C. DAPI was
311 used at a concentration of 1 µg/mL as a viability marker. CD34⁺ cells were then sorted in a BD
312 INFLUX™ (BD Biosciences) or BD FACSAria II (BD Biosciences) as previously shown (Rio et
313 al., 2019). Purified CD34⁺ cells were directly used for scRNA seq analysis and small aliquots
314 stored at -80°C for vector copy number analysis.

315 **Analysis of lentiviral vector copy numbers in total BM and purified CD34⁺ cells**

316 The number of proviral copies per cell (VCN/cell) was analyzed after genomic extraction of the
317 DNA using the DNA easy blood and tissue kit (Qiagen) or by proteinase K lysis as previously
318 described (Rio et al., 2019). Duplex qPCR was conducted to detect the *Psi* sequence of the
319 provirus and the *Albumin*, as a control gene. To amplify *Psi* sequence: *Psi* forward (*Psi.F*): 5'
320 CAGGACTCGGCTTGCTGAAG 3' and *Psi* reverse (*Psi.R*): 5'
321 TCCCCCGCTTAATACTGACG 3' primers were used and detected with the Taqman probe
322 *Psi.P* FAM: 5'CGCACGGCAAGAGGCGAGG3'. To normalize to endogenous *Albumin*,

323 specific primers for *Albumin* were used: *Alb* forward (*Alb.F*): 5'
324 GCTGTCATCTCTTGTGGGCTG 3' and *Alb* reverse (*Alb.R.*): 5'
325 ACTCATGGGAGCTGCTGGTTC 3' together with a Taqman probe *Alb.P* VIC: 5'
326 CCTGTCATGCCCACACAAATCTCTCC 3'. qPCR was conducted in an Applied 7500 Fast
327 Real Time PCR system (Thermo Fisher Scientific), as previously described (Rio et al., 2019).

328 **Single-cell RNA-sequencing (scRNA-seq)**

329 The transcriptome of BM CD34⁺ cells was investigated using NEXTGEM Single Cell 3' Reagent
330 Kits v3.1 (10X Genomics) according to the manufacturer's instructions. Between 2,000 and
331 6,000 CD34⁺ cells were loaded at a concentration of 700-1,000 cells/ μ L on a Chromium
332 Controller instrument (10X Genomics) to generate single-cell gel bead-in-emulsions (GEMs). In
333 this step, each cell was encapsulated with primers containing a fixed Illumina Read 1 used to
334 sequence a cell-identifying 16 bp 10X barcode for each cell and a 12 bp Unique Molecular
335 Identifier (UMI) for each transcript. Upon cell lysis, reverse transcription yielded full-length,
336 barcoded cDNA. This cDNA was then released from the GEMs, PCR-amplified and purified
337 with magnetic beads (SPRIselect, Beckman Coulter). Enzymatic Fragmentation and Size
338 Selection was used to optimize cDNA size prior to library construction. Fragmented cDNA was
339 then end-repaired, A-tailed and ligated to Illumina adaptors. A final PCR-amplification with
340 barcoded primers allowed sample indexing. Library quality control and quantification was
341 performed using Qubit 3.0 Fluorometer (Life Technologies) and Agilent's 4200 TapeStation
342 System (Agilent), respectively. Sequencing was performed in a NextSeq500 (Illumina) (Read1:
343 28 cycles; Read 55 cycles; i7 index: 8 cycles) at an average depth of 20,000 reads/cell.
344 According to these analyses CD34⁺ cell populations were classified as *corrected* (FANCA⁺) and
345 *uncorrected* (FANCA⁻) cells, considering that FANCA⁻ is enriched with cells that only express
346 the endogenous mutated *FANCA* mRNA, while FANCA⁺, that includes cells with higher
347 *FANCA* expression, is enriched with cells that express both the endogenous mutated *FANCA*
348 plus the ectopic functional *FANCA* mRNA.

349 **scRNA-seq: bioinformatics**

350 Data filtering and normalization: Sequenced libraries were demultiplexed, aligned to human
351 transcriptome (hg38) and quantified using Cell Ranger (v_3.0.1). Ongoing analysis was
352 conducted using Seurat (V_3.2.0)(Stuart, Butler et al., 2019) in R (V_3.5.2) (Team, 2019).

353 Quality control filters based on the number of detected genes, number of UMIs and percentage of
354 mitochondrial UMIs were performed to each one of the samples. The thresholds were defined
355 based on the distribution of the previously mentioned parameters and visual inspection of quality
356 control scatter plots. After filtering of low quality cells, a total number of 14,208 (FA-02002),
357 720 (FA-02004), 1,438 (FA-02006), 1,995 (FA-02008), and 12,549 (HD) cells were retained.

358 Each single cell dataset was individually normalized, using the Normalize Seurat function.
359 Feature counts for each cell were divided by the total counts for that cell and multiplied by the
360 scale factor. This was then natural-log transformed. The data was regressed out by cell cycle
361 stadium, number of features and number of counts. Non-linear dimensional reduction was
362 performed (UMAP) to plot the data of each sample. PCA was defined as dimensional reduction
363 to use in the UMAP graph. Each of the FA samples was integrated with the healthy donor
364 sample.

365 Cell annotation: For cell annotation, we use the annotation conducted in three additional human
366 samples of healthy young individuals (3YI). The isolation protocol of 3YI includes the cell types
367 in the 4 FA patients and the HD: Ficoll-Paque Plus (GE healthcare) density gradient
368 centrifugation and stained using CD34 (clone 8G12; BD bioscience) CD64 (clone 10.1;
369 Biolegend) CD19 (clone SJ25C1; Biolegend) CD10 (clone HI10A; Biolegend) CD3 (clone
370 OKT3; Biolegend) CD36 (clone CLB-IVC7; Sanquin Plesmanlaan) CD61 (clone RUU-PL7F12;
371 BD bioscience) for 15 min at RT. And finally, CD34+ CD64- CD19- CD10- CD3-CD36+CD61+
372 cells were then sorted in a BD FACSAria II (BD Biosciences) as previously shown. The data-
373 analysis processing of those samples was conducted as the protocol described for FA samples.
374 Next, we performed unsupervised clustering with the Louvain algorithm as implemented in
375 Seurat (Blondel, Guillaume et al., 2008). We tested several resolution values and assessed the
376 results by calculating the average silhouette for each cluster. We determined the cluster markers
377 using the Seurat function FindAllMarkers, with the MAST method. Finally, we annotated the
378 clusters in 3YI by manually inspecting the most specific markers and looking for curated
379 markers in the literature. Using the robust annotation conducted in 3YI, the “label transfer
380 function” from Seurat was used to annotate the four FA and the HD samples (Stuart et al., 2019).
381 It is important to note that while the annotation of the 3YI is valid for the annotation of FA and
382 HD samples, we decided not to include the 3YI samples in the analysis as the cell proportions
383 may be different based on the isolation protocol.

384 Differential expression analysis: The differential expression analysis was conducted using
385 FindMarkers function in the Seurat package. Genes were considered differentially expressed if
386 $|\logFC| > 0.25$ and adjusted p-value < 0.05 .

387 GSEA analysis: Gene set enrichment analyses were conducted using ClusterProfiler (version
388 3.10.1)(Blondel et al., 2008) in R(Team, 2019). The normalized data of each sample and cell
389 type was ranked by the logFC value and the analysis was run comparing our data with GO
390 biological processes. A gene set was considered significantly enriched if GO adjusted p-
391 value < 0.05 .

392 **Pathway visualization**

393 After GSEA analysis two core pathways were selected (Cell cycle and FA/BRCA) for
394 visualization purpose using Cytoscape (version 3.8.2.) (Shannon, Markiel et al., 2003). The
395 values of logFC were for each one of the samples and different contrast using omic visualizer
396 package. The pathways are shown as imported in the Cytoscape package; for two genes an
397 alternative gene symbol is shown (MHF, RPA).

398 **Analysis of the sensitivity of hematopoietic colony forming cells to the genotoxic agent** 399 **mitomycin C**

400 To assess the influence that gene therapy had in the response of FA hematopoietic progenitors to
401 mitomycin C (MMC), the number of colonies generated in the absence and the presence of this
402 agent was assessed. In these experiments a total number of 2.5×10^5 BM cells were plated in
403 plates containing 1 mL methylcellulose medium (Methocult™ #H4434) supplemented with 10
404 $\mu\text{g/mL}$ anti-TNF α and 1 mM N-acetylcysteine, in the absence and the presence of 10 nM MMC
405 (Sigma-Aldrich). Cells were then cultured for 14 days at 37°C, 5% CO $_2$ and 5% O $_2$, and colonies
406 were then scored under an inverted microscope.

407 **Chromosomal instability test in peripheral blood T cells**

408 The diepoxybutane (DEB)-induced chromosomal instability test was carried out in peripheral
409 blood (PB) T cells from the FA patients prior to and in the long-term after infusion of corrected
410 cells. After 24h of culture, PB cells were incubated in the absence or the presence of DEB
411 (0.1 $\mu\text{g/mL}$; Sigma-Aldrich), and forty-six hours later colcemid was added (Gibco; 0.1 $\mu\text{g/mL}$).
412 Two hours later, metaphase spreads were obtained and stained with Giemsa. Fifty metaphases

413 were analyzed from DEB-treated and 25 metaphases from unexposed cultures in a Zeiss Imager
414 M1 microscope coupled to a computer assisted metaphase finder (Metasystems). Criteria for the
415 determination and quantification of chromosome breakage were previously described (Castella,
416 Pujol et al., 2011).

417 **Telomere length studies**

418 DNA was extracted from patient's blood samples and the telomere length was determined by
419 quantitative PCR as previously described (Cawthon, 2002). In this method the amount of
420 telomere DNA (T) and of the single copy *36B4* reference gene (S) were determined by
421 quantitative PCR for each blood sample. The ratio between these two parameters (T/S) was a
422 measure of the relative telomere length. A control DNA isolated from the cultured cell line
423 MCF-7 was used as an internal control in each experiment to normalize the T/S ratio obtained for
424 the experimental samples. The telomere length of each sample was calculated from the
425 normalized T/S ratios using the formula: telomere length in Kbp = T/S x 3.86 + 1.89. Three
426 independent experiments with triplicates were conducted for each sample.

427 **Basic statistical tests**

428 *Proportion test:* In each FA sample and cell type, a two-proportion statistical test was conducted
429 to investigate significant differences in cell type proportion between FANCA⁺ and FANCA⁻ cells
430 in each CD34⁺ subpopulation.

431 *Annova test:* We conducted a two-tail ANOVA test to investigate the differences of FANCA
432 expression between therapy treated patients among the FANCA⁺ set for each CD34⁺ cell
433 subpopulation.

434 *Wilcoxon test:* The comparison of the expression of the FANCA gene between FANCA⁺ cells in
435 FA integrated samples and HDs was performed using a two-sided Wilcoxon test for each CD34⁺
436 cell subpopulation. In HD, only cells with >0 FANCA gene expression value were considered.

437 *Binomial Test:* We conducted a binomial test to investigate if the shared directionality of changes
438 for two contrasts, "FANCA⁺ vs FANCA⁻" and "HD vs FANCA⁺", was significantly over-
439 represented. To this end, the genes sharing the same directionality for both contrasts were
440 classified as 1, and 0 otherwise; the binomial was conducted considering a probability of 0.5,

441 number of experiments of 382 and a one-tail p-value associated to values larger than the
442 observed. The analysis was conducted separately for each cell type and sample.

443 *Binary Correlation:* We conducted a binary correlation analysis between the directionality of the
444 same genes in the two contrasts, “FANCA⁺ vs FANCA⁻” and “HD vs FANCA⁺”. All the
445 upregulated genes were classified as 1 and the downregulated as 0. A binary correlation test was
446 conducted using R.

447 *General considerations:* To perform all the statistical tests R (Team, 2019) was used. In all the
448 cases the multiple testing was addressed using Bonferroni; and for any analysis the null
449 hypothesis was rejected if adjusted p-value <0.05.

450

451 **ACKNOWLEDGMENTS**

452 The authors thank Ramón García-Escudero for careful reading of the manuscript and helpful
453 discussions. The authors also thank A. de la Cal for coordinating the delivery of BM samples
454 from patients with FA. The authors are also indebted to the patients with FA, their families and
455 clinicians from the Fundación Anemia de Fanconi. This work was supported by grants from the
456 European Commission’s Seventh Framework Program (HEALTH-F5-2012-305421) to the
457 EUROFANCOLEN Consortium J.B. and J.Se; from Ministerio de Ciencia, Innovación y
458 Universidades and Fondo Europeo de Desarrollo Regional (RTI2018-097125-B-I00 to P.R. and
459 S.N.); from Gobierno de Navarra, Departamento de Desarrollo Económico y Empresarial
460 (AGATA 0011-1411-2020-000010); from Instituto de Salud Carlos III (ISCIII) and co-financed
461 by FEDER CIBERONC (CB16/12/00489 and CB16/12/00225); Redes de Investigación
462 Cooperativa (TERCEL RD16/0011/0005) and from Consejería de Educación, Juventud y
463 Deporte de la Comunidad de Madrid (AvanCell Project; B2017/BMD3692); from Fondo de
464 Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain, grant number PI20/0335 and co-
465 funded by European Regional Development (FEDER) funds. M.A. was supported by a PhD
466 Fellowship from Ministerio de Ciencia, Innovación y Universidades (FPU18/05488). CIBERER
467 and CIBERONC are initiatives of the Instituto de Salud Carlos III and Fondo Europeo de
468 Desarrollo Regional.

470 **AUTHORSHIP CONTRIBUTIONS**

471 M.L., P.R., A.V-Z., N.P., S.N., D.A, B.F-V, R.M.J, M.A, A.U-A., R.P, L.S and D-G.C
472 performed the experimental studies and analyzed the data. J.Se. and J.Z. provided critical
473 materials. M.L., P.R., D-G.C, F.P. J.A.B wrote the manuscript. E.N. and J.D.S. reviewed the
474 manuscript. P.R., S.N., D-G.C, F.P. J.A.B designed the study. All authors discussed the results
475 and contributed to the preparation of the manuscript.

476 **CONFLICT OF INTEREST**

477 The Hematopoietic Innovative Therapies Division at CIEMAT receives funding and has licensed
478 the PGK-FANCA-WPRE* lentiviral vector to Rocket Pharmaceuticals. J.A.B. and J.Se. are
479 consultants for Rocket Pharmaceuticals. E.N. and J.D.S. are employees of Rocket
480 Pharmaceuticals. P.R., S.N., J.S and J.A.B. are inventors on patents filed by CIEMAT,
481 CIBERER and Fundación Jiménez Díaz, and may be entitled to receive financial benefits from
482 the licensing of such patents. The rest of the authors declare that they have no competing
483 interests.

484 **THE PAPER EXPLAINED**

485 **PROBLEM:** HSC gene therapy of monogenic diseases has already demonstrated clinical
486 efficacy in a variety of monogenic disorders, including HSC diseases such as Fanconi anemia
487 (FA). Nevertheless, the question of whether or not these therapies can correct the transcriptional
488 program of target cells, in particular of diseased HSCs, has never been addressed.

489 **RESULTS:** In this study we demonstrate that gene therapy reverts the transcriptional signature
490 of HSPCs from patients with FA. Remarkably, these HSCs changed their transcriptional
491 program, to resemble the one corresponding to healthy donor HSPCs, and this is associated with
492 the phenotypic correction of FA HSPCs.

493 **IMPACT:** Our results show for the first time the potential of gene therapy to rescue defects in
494 the HSPC transcriptional program from patients with inherited diseases, in this particular case in
495 a disease characterized by profound defects in the HSCs.

496 **FOR MORE INFORMATION**

497 <https://anemiadefanconi.org/>

498 <http://www.fanconi.org/>

499

500 **DATA SHARING STATEMENT**

501 Data supporting the findings of this study are available at:

502 <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE180536>

503 **REFERENCES**

504

505 Blondel VD, Guillaume J-L, Lambiotte R, Lefebvre E (2008) Fast unfolding of communities in
506 large networks. *Journal of Statistical Mechanics: Theory and Experiment* P10008

507 Brosh RM, Jr., Bellani M, Liu Y, Seidman MM (2017) Fanconi Anemia: A DNA repair disorder
508 characterized by accelerated decline of the hematopoietic stem cell compartment and other
509 features of aging. *Ageing Res Rev* 33: 67-75

510 Castella M, Pujol R, Callen E, Ramirez MJ, Casado JA, Talavera M, Ferro T, Munoz A, Sevilla
511 J, Madero L, Cela E, Belendez C, de Heredia CD, Olive T, de Toledo JS, Badell I, Estella J, Dasi
512 A, Rodriguez-Villa A, Gomez P et al. (2011) Chromosome fragility in patients with Fanconi
513 anaemia: diagnostic implications and clinical impact. *J Med Genet* 48: 242-50

514 Cawthon RM (2002) Telomere measurement by quantitative PCR. *Nucleic Acids Res* 30: e47

515 Ceccaldi R, Parmar K, Mouly E, Delord M, Kim JM, Regairaz M, Pla M, Vasquez N, Zhang QS,
516 Pondarre C, Peffault de Latour R, Gluckman E, Cavazzana-Calvo M, Leblanc T, Larghero J,
517 Grompe M, Socie G, D'Andrea AD, Soulier J (2012) Bone marrow failure in Fanconi anemia is
518 triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and
519 progenitor cells. *Cell stem cell* 11: 36-49

520 Ferrari G, Thrasher AJ, Aiuti A (2021) Gene therapy using haematopoietic stem and progenitor
521 cells. *Nat Rev Genet* 22: 216-234

522 Flach J, Bakker ST, Mohrin M, Conroy PC, Pietras EM, Reynaud D, Alvarez S, Diolaiti ME,
523 Ugarte F, Forsberg EC, Le Beau MM, Stohr BA, Mendez J, Morrison CG, Passegue E (2014)
524 Replication stress is a potent driver of functional decline in ageing haematopoietic stem cells.
525 *Nature* 512: 198-202

526 Gonzalez-Murillo A, Lozano ML, Alvarez L, Jacome A, Almarza E, Navarro S, Segovia JC,
527 Hanenberg H, Guenechea G, Bueren JA, Rio P (2010) Development of lentiviral vectors with
528 optimized transcriptional activity for the gene therapy of patients with Fanconi anemia. *Hum*
529 *Gene Ther* 21: 623-30

530 Jaber S, Toufektchan E, Lejour V, Bardot B, Toledo F (2016) p53 downregulates the Fanconi
531 anaemia DNA repair pathway. *Nature communications* 7: 11091

532 Rego MA, Harney JA, Mauro M, Shen M, Howlett NG (2012) Regulation of the activation of the
533 Fanconi anemia pathway by the p21 cyclin-dependent kinase inhibitor. *Oncogene* 31: 366-75

534 Rio P, Navarro S, Wang W, Sanchez-Dominguez R, Pujol RM, Segovia JC, Bogliolo M, Merino
535 E, Wu N, Salgado R, Lamana ML, Yanez RM, Casado JA, Gimenez Y, Roman-Rodriguez FJ,
536 Alvarez L, Alberquilla O, Raimbault A, Guenechea G, Lozano ML et al. (2019) Successful
537 engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi
538 anemia. *Nat Med* 25: 1396-1401

539 Rodríguez A, Zhang K, Färkkilä A, Filiatrault J, Yang C, Velázquez M, Furutani E, Goldman
540 DC, García de Teresa B, Garza-Mayén G, McQueen K, Sambel LA, Molina B, Torres L,
541 González M, Vadillo E, Pelayo R, Fleming WH, Grompe M, Shimamura A et al. (2021) MYC
542 Promotes Bone Marrow Stem Cell Dysfunction in Fanconi Anemia. *Cell stem cell* 28: 33-47.e8

543 Savage SA, Alter BP (2008) The role of telomere biology in bone marrow failure and other
544 disorders. *Mech Ageing Dev* 129: 35-47

545 Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B,
546 Ideker T (2003) Cytoscape: a software environment for integrated models of biomolecular
547 interaction networks. *Genome Res* 13: 2498-504

548 Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, 3rd, Hao Y, Stoeckius
549 M, Smibert P, Satija R (2019) Comprehensive Integration of Single-Cell Data. *Cell* 177: 1888-
550 1902.e21

551 Team RC (2019) A language and environment for statistical computing. R Foundation for
552 Statistical Computing, Vienna, Austria.

553 Velten L, Haas SF, Raffel S, Blaszkiewicz S, Islam S, Hennig BP, Hirche C, Lutz C, Buss EC,
554 Nowak D, Boch T, Hofmann WK, Ho AD, Huber W, Trumpp A, Essers MA, Steinmetz LM
555 (2017) Human haematopoietic stem cell lineage commitment is a continuous process. *Nat Cell*
556 *Biol* 19: 271-281

557 Zhang H, Kozono DE, O'Connor KW, Vidal-Cardenas S, Rousseau A, Hamilton A, Moreau L,
558 Gaudio EF, Greenberger J, Bagby G, Soulier J, Grompe M, Parmar K, D'Andrea AD (2016)
559 TGF- β Inhibition Rescues Hematopoietic Stem Cell Defects and Bone Marrow Failure in
560 Fanconi Anemia. *Cell stem cell* 18: 668-81

561 Zheng GX, Terry JM, Belgrader P, Ryvkin P, Bent ZW, Wilson R, Ziraldo SB, Wheeler TD,
562 McDermott GP, Zhu J, Gregory MT, Shuga J, Montesclaros L, Underwood JG, Masquelier DA,
563 Nishimura SY, Schnall-Levin M, Wyatt PW, Hindson CM, Bharadwaj R et al. (2017) Massively
564 parallel digital transcriptional profiling of single cells. *Nature communications* 8: 14049

565

566

567 **FIGURE LEGENDS**

568

569

570

571

572

573

574

575

576

577

Figure 1. Experimental design of scRNAseq analyses performed in FA-A patients 2-5 years after lentiviral-mediated gene therapy. Four FA-A patients who had been treated by *ex vivo* lentiviral-mediated gene therapy in the absence of conditioning were included in this study. At 2-5 years post-gene therapy, these patients harbored a chimeric population of corrected and uncorrected hematopoietic stem and progenitor cells (HSPCs) in their bone marrow (BM). Aliquots of BM CD34⁺ cells from these patients were sorted and processed for single-cell RNA-seq. Bioinformatic analyses were then conducted to comparatively investigate changes in the transcriptional program of corrected *versus* uncorrected HSPCs, coexisting in each of the gene therapy treated patients.

578

579

Figure 2. scRNAseq analysis of corrected and uncorrected hematopoietic stem and progenitor cells from FA-A patients 2-5 years after lentiviral-mediated gene therapy.

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

(A) UMAP plot showing the clustering analysis for BM CD34⁺ cells from a FA-A patient previously treated by gene therapy (FA-02006 patient as an example; see **Fig. S1** for patients FA-02002, FA-02004 and FA-02008). A total of 12 clusters were identified, spanning the different HSPC subpopulations. Identified clusters include an HSC cluster (hematopoietic stem cell; brown). Clusters with megakaryocytic-erythroid identity include MEP (erythroid-megakaryocyte progenitor; purple), Erythroid (erythroid progenitor; pink), and Basophils (basophil progenitor; light pink). Clusters with lympho-myeloid identity include LMPP (lymphoid-primed multipotent progenitor; light blue), Cycling-LMPP (blue), CLP (common lymphoid progenitor; orange), GMP1 and GMP2 (granulocyte-monocyte progenitor; light green and green), Monocytes (monocyte progenitor; red), DC (dendritic cell progenitor; nude), and PreB (B cells progenitor; light purple). (B) The same UMAP as shown in panel A, highlighting the distribution of FANCA⁺ cells (FANCA mRNA detectable; red) versus FANCA⁻ cells (FANCA mRNA levels are below detection limit; blue). (C) Barplot showing the total number of cells in the different HSPC populations corresponding to the four gene therapy treated patients. In each case, the number of FANCA⁺ (red) and FANCA⁻ (blue) cells is shown and the percentage represented by FANCA⁺ is written in the top of the bar. (D) Boxplot of integrated and normalized FANCA gene expression in FANCA⁺, depicted by cell type and FA individual (n=3). (E) Barplot representation of the differential expression analysis between FANCA⁺ and

598 FANCA⁻ for each FA patient (n=4) and for each of the HSPC populations. In each case, the
599 number of upregulated and downregulated genes is shown. Upregulated genes were defined as
600 logFC>0.25 (orange), upregulated and significant genes were defined as a logFC>0.25 and
601 adjusted p-value<0.05 (red), downregulated genes were defined as a logFC<-0.25 (light blue)
602 and downregulated and significant genes were define as logFC<-0.25 and adjusted p-value<0.05
603 (dark blue). The number of genes with the same behavior (upregulated or downregulated) in the
604 four individuals is shown below each HSPCs (labeled as “shared”).

605 **Figure 3. Comparisons of the gene expression signature between corrected and uncorrected**
606 **HSPCs coexisting in gene therapy treated FA patients.**

607 **(A) Left larger panel:** UMAP plot showing the clustering analysis of CD34⁺ BM cells after
608 integration of data from a gene therapy treated FA-A patient and a healthy donor (FA-02006 is
609 included as a representative example; see Fig. S2 for the rest of individuals). **Right smaller**
610 **panel:** the same UMAP as shown in left panel but highlighting the distribution of HD HSPCs
611 (yellow), FANCA⁺ HSPCs (red) and FANCA⁻ HSPCs (blue). Clusters identification as in Figure
612 1. **(B)** Boxplot representation of normalized single-cell FANCA expression of FANCA⁺ cells
613 (red) and HD cells (yellow) by HSPC cluster. For each cell type, differences in the expression
614 levels between the ectopic expression of FANCA from corrected FA CD34⁺ cells and expression
615 levels corresponding to HD CD34⁺ cells are shown (*adjusted p-value <0.05; **adjusted p-value
616 < 0.01; ***adjusted p-value < 0.001) **(C)** The figure shows the results associated to three
617 differential expression contrasts: FANCA⁺ vs FANCA⁻ HSPCs from GT-treated FA patients; HD
618 HSPCs vs FANCA⁻ HSPCs from GT-treated patients; and HD HSPCs vs FANCA⁺ HSPCs from
619 GT-treated patients. The second row shows the twelve different CD34⁺ cell types, and the third
620 one the sample identification from each of the four GT-treated patients. Up-regulated genes
621 (logFC>0) are shown in orange and those with significant upregulation in red (logFC>0.25 and
622 adjusted p-value<0.05). Down-regulated genes (logFC<0) are shown in light blue and those with
623 significant downregulation in dark blue (logFC<-0.25 and adjusted p-value<0.05). Unsupervised
624 hierarchical clustering using Pearson distance and average linkage method was applied for gene
625 classification. The genes included in the heatmap are those that for at least one cell type are
626 identified as differentially expressed (abs(logFC)>0.25 and adjusted p-value<0.05) in “at least
627 three patients”, and “showing the same direction of the change for the three patients”, when

628 considering the contrast FANCA⁺ vs FANCA⁻ (n=152; see the entire list in Table S2). FANCA
629 was excluded from the list.

630 **Figure 4. Restored gene expression pathways associated to the ectopic expression of**
631 **FANCA in HSPCs from gene therapy treated FA patients.**

632 Comparative density plots showing the distribution of differential expression derived logFC for a
633 selected set of pathways. For each patient, paired comparisons between FANCA⁺ vs FANCA⁻
634 HSPCs from GT-treated FA patients and HD HSPCs vs FANCA⁻ HSPCs are shown. The
635 complete name of the pathways with numbers are: (1) DNA damage response, detection of DNA
636 damage, (2) telomere maintenance via semi-conservative replication, (3) double-strand break
637 repair via homologous recombination, (4) double-strand break repair via nonhomologous end
638 joining, (5) positive regulation of G2/M transition of mitotic cell cycle, and (6) negative
639 regulation of G2/M transition of mitotic cell cycle.

640 **Figure 5. Restored gene expression of key pathways in corrected HSPCs from gene therapy**
641 **treated FA patients.**

642 (A) Upregulated and downregulated genes implicated in cell cycle control. The figure represents
643 the logFC associated to two contrasts: FANCA⁺ vs FANCA⁻ HSPCs from GT-treated FA
644 patients (internal crowns), and HD HSPCs vs FANCA⁻ HSPCs from GT-treated patients
645 (external crowns). Each external and internal crown is divided in four parts, each of them
646 representing one FA patient. Upregulated genes are shown in red and downregulated genes in
647 blue. (B) Same representation as in A showing changes in the expression of genes participating
648 in the FA/BRCA pathway.

649
650 **Figure 6: Functional implications associated to the restoration of DNA repair and telomere**
651 **biology pathways**

652 (A) Survival to mitomycin C (MMC; 10 nM) of BM colony forming cells (CFCs) from FA-A
653 patients shown in Figures 1-5 prior and after infusion of gene corrected cells. (B) Percentage of
654 PB T cells with chromosomal aberrations induced by diepoxibutane (DEB), prior to and after
655 gene therapy. (C) Analysis of the telomere length of PB cells from FA-A patients shown in
656 Figures 1-5 at 15th day post-infusion, when corrected cells were still undetectable, to the 2nd -5th
657 year post-infusion of gene corrected cells. As a negative control, three FA patients with no

658 significant engraftment of gene corrected cells are included. Dashed lines correspond to telomere
659 lengths corresponding to HD age matched PB cells. Time-points of the MMC, DEB and telomere
660 analyses are the same or the closest ones corresponding to the scRNAseq analyses shown in
661 Figures 1-5.

662

663

664

EXPANDED VIEW FIGURES LEGENDS

665 **Expanded view Figure S1:** (A) Left panel: UMAP plot showing the clustering analysis for
666 CD34⁺ BM cells from the FA-02002 patient undergoing FANCA gene therapy. A total of 12
667 clusters were identified, spanning the different HSPC subpopulations. Identified clusters include
668 an HSC cluster (hematopoietic stem cell; brown). Clusters with megakaryocytic-erythroid
669 identity include MEP (erythroid-megakaryocyte progenitor; purple), Erythroid (erythroid
670 progenitor; pink), and Basophils (basophil progenitor; light pink). Clusters with lympho-myeloid
671 identity include LMPP (lymphoid-primed multipotent progenitor; light blue), Cycling-LMPP
672 (blue), CLP (common lymphoid progenitor; orange), GMP1 and GMP2 (granulocyte-monocyte
673 progenitor; light green and green), Monocytes (monocyte progenitor; red), DC (dendritic cell
674 progenitor; nude), and PreB (B cells progenitor; light purple). Right panel: Distribution of
675 FANCA positive cells (corrected cells; red) versus FANCA negative cells (uncorrected cells;
676 blue). (B, C) Same as (A), including the analysis of the FA-02004 and FA-02008 respectively
677 patient. (D) Cell type proportions for each individual separating in each case FANCA⁺ and
678 FANCA⁻ cells.

679

680 **Expanded view Figure S2:** (A) UMAP plot showing the clustering analysis for CD34⁺ BM cells
681 from the FA-02002 patient undergoing FANCA gene therapy and the healthy donor. A total of
682 12 clusters were identified, spanning the different HSPC subpopulations. Identified clusters
683 include an HSC cluster (hematopoietic stem cell; brown). Clusters with megakaryocytic-
684 erythroid identity include MEP (erythroid-megakaryocyte progenitor; purple), Erythroid
685 (erythroid progenitor; pink), and Basophils (basophil progenitor; light pink). Clusters with
686 lympho-myeloid identity include LMPP (lymphoid-primed multipotent progenitor; light blue),
687 Cycling-LMPP (blue), CLP (common lymphoid progenitor; orange), GMP1 and GMP2
688 (granulocyte-monocyte progenitor; light green and green), Monocytes (monocyte progenitor;

689 red), DC (dendritic cell progenitor; nude), and PreB (B cells progenitor; light purple). **(B, C)**
690 Same as (A), including the analysis of the FA-02004 and FA-02008 respectively patient. **(D)**
691 Distribution of cells classified as cells derived from the healthy donor (yellow), FANCA⁺ cells
692 (red) and FANCA⁻ cells (blue) for FA-02002 patient. **(E, F)** Same as (D) including the analysis
693 of the FA-02004 and FA-02008 respectively patient.





Figure 1









Figure 3

Gene Set Analysis Monocytes





Figure 4

A Cell cycle - Monocytes



B FA/BRCA - Monocytes




Figure 5